Premium
A patient with plaque‐stage mycosis fungoides has successfully been treated with long‐term administration of IFN‐γ and has been in complete remission for more than 6 years
Author(s) -
HORIKOSHI T.,
ONODERA H.,
EGUCHI H.,
HANADA N.,
FUKUZAWA K.,
TAKAHASHI M.,
ISHIHARA K.,
IKEDA S.
Publication year - 1996
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1996.d01-752.x
Subject(s) - mycosis fungoides , medicine , exacerbation , stage (stratigraphy) , surgery , refractory (planetary science) , gastroenterology , complete remission , mycosis , dermatology , chemotherapy , lymphoma , paleontology , physics , astrobiology , biology
Summary We report the successful treatment of a patient with plaque‐stage mycosis fungoides with long‐term and intravenous administration of recombinant human interferon‐γ (IFN‐γ) and discuss the possible mechanisms of this therapy. A 55‐year‐old female patient had been resistant to existing treatments and had suffered repeated exacerbations over a 5‐year period. Four weeks after initiation of 2 × 10 6 U/day of IFN‐γ. a > 10% decrease in the affected surface area was noted. Twenty‐two weeks after the administration of 228 × 10 6 U of IFN‐γ, complete remission (CR) was obtained. The CR continued for 13 weeks, but this was followed by an exacerbation. The second CR was obtained after the IFN‐γ dosage was increased to 16 × 10 6 U/week. The dosage was then gradually reduced by 2–4 × 10 6 U every 2 or 3 months. She was treated with a total dose of 2814 × 10 6 of IFN‐γ. She has been followed up for more than 6 years, and there has been no recurrence of mycotic skin lesions nor any visceral involvement. During therapy, no serious side‐effects were noted. Long‐term administration of IFN‐γ is useful for the treatment of patients with intractable mycosis fungoides. A gradual decrease in the dose of IFN‐γ is important for maintaining remission.